|
| Application | Reference | Cell line | Product | Authors’ stated main result |
|
| Bone regeneration | [32] | MC3T3 mouse osteoblast cell line | Composite PCLHS coated on biodegradable Mg alloy | PCLHS-NFs increase both bone regeneration and control its degradation |
| [45] | - | FCN loaded with β-TCP-SIM-NFMS | FCN-β-TCP-SIM-NFMs revealed better cell proliferation and attachment than the control fiber |
| [33] | MC3T3-E1 osteoblast cells | PGS-HA-SIM composite NFs | PCL-PGS-HA-NFs are suitable for both increasing bone tissue regeneration and controlled drug release |
| [46] | MC3T3-E1 | PCL-PTS-NFs | PCL-PTS-NFs both cause controlled drug release and increase cell regeneration and adhesion compared to the control group (PCL) |
| [31] | Human adipose-derived stem cells (hADSCs) | PVA-SF core-shell NFs with RSV | PVA-SF core-shell NFs with RSV increased cell proliferation and osteogenic differentiation |
| [47] | Human adipose-derived stem cells (hADSCs) | SF-RSV-P3-NFs | SF-RSV-P3 with RSV sustained release enhanced osteogenesis |
|
| Endothelization and antithrombotic effects | [48] | Vascular endothelial cells (HUVECs) | AtvCa in the inner of PLCL-NFs-covered stents | AtvCa-PLCL-controlled release NFs-covered stents cause HUVEC proliferation in a dose-dependent manner |
| [39] | Smooth muscle cells (SMCs) | A heparin-Rosu-loaded P(LLA-CL) NF-covered stent | The heparin-Rosu-loaded P(LLA-CL) NF-covered stent declined SMC proliferation with enhancement of Rosu concentration |
| [40] | Rabbit aneurysm model | Rosu-calcium-heparin-loaded PLCL scaffold | Rosu 100 exhibited the best reendothelization and intima coverage results among all other covered stents |
| [41] | HUVECs | Heparin-Rosu-calcium-loaded P(LLA-CL) NFs-covered stents | Heparin-Rosu-calcium-loaded P(LLA-CL) NFs shows a significant anticoagulation ability |
| [42] | SMCs | Rosu-paclitaxel-NFs bifurcation stents | The Rosu-paclitaxel-NF-covered stent declined SMC proliferation and platelets adhesion |
|
| Anti-inflammation | [43] | THP-1 cell culture | Atorvastatin-PCL NFs | Atorvastatin-PCL NFs of 60% inhibited TNF-α and 80% inhibited IL-6 |
|
